Growth Hormone Secretagogues Compared: Ipamorelin, CJC-1295, Tesamorelin, and GHRP-6 Research Profiles

Growth hormone secretagogues compared across the four most studied compounds split cleanly along receptor mechanism: Ipamorelin and GHRP-6 are GHS-R1a (ghrelin receptor) agonists, while CJC-1295 and Tesamorelin act on the GHRH receptor. Ipamorelin shows the cleanest selectivity, releasing GH without the ACTH and cortisol response that GHRP-6 produces; CJC-1295 with DAC has by far the longest duration of action because it binds covalently to serum albumin; Tesamorelin is a DPP-IV-resistant GHRH(1-44) analogue and the only one of the four with a regulatory approval; and GHRP-6 is the first-generation reference compound with the broadest hormonal footprint. Which one fits a protocol depends on whether the study design calls for pulsatile or sustained GH elevation.

Growth hormone secretagogue research encompasses a diverse class of peptides that stimulate endogenous growth hormone (GH) release through distinct receptor mechanisms. For researchers in Canada designing experiments around GH-axis modulation, understanding the comparative pharmacology of these compounds is critical to selecting the right tool for specific research questions.

This comparative analysis reviews the preclinical and mechanistic evidence for four of the most widely studied growth hormone secretagogues: Ipamorelin, CJC-1295, Tesamorelin, and GHRP-6. Each operates through a different mechanism, produces distinct GH release profiles, and carries different implications for experimental design.

Overview: Two Pathways to GH Release

Growth hormone secretagogues operate through two primary receptor systems. Ghrelin receptor (GHS-R1a) agonists like Ipamorelin and GHRP-6 stimulate GH release by mimicking endogenous ghrelin signaling at the pituitary and hypothalamic level. Growth hormone-releasing hormone (GHRH) analogs like CJC-1295 and Tesamorelin act on the GHRH receptor (GHRH-R) to amplify the natural pulsatile GH signal.

The two pathways are not redundant. Bowers and colleagues showed in 1990 (Journal of Clinical Endocrinology and Metabolism 70:975-982) that GHRP-6 and GHRH given together release more GH than the sum of either alone, and in rats (Bowers et al., 1991, Endocrinology 128:2027-2035) that this synergy could not be explained either by GHRP-6 releasing endogenous GHRH or by inhibition of somatostatin, which pointed to a separate receptor and signalling route. That receptor was later cloned as GHS-R1a and its endogenous ligand identified as ghrelin. The synergy is the reason combination designs, one agonist for each receptor, appear so often in preclinical GH-axis work.

Ipamorelin: Selective GH Secretagogue

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂; molecular formula C₃₈H₄₉N₉O₅, MW 711.85 g/mol) is a pentapeptide GHS-R1a agonist distinguished by its selectivity. Unlike earlier ghrelin mimetics, Ipamorelin demonstrates no measurable effect on ACTH or cortisol release at GH-stimulating concentrations.

The defining study is Raun and colleagues (1998, European Journal of Endocrinology 139:552-561), which characterised the compound in rat pituitary cells, anaesthetised rats and conscious swine. In vitro, Ipamorelin released GH with an EC₅₀ of 1.3 nM and a maximal response of 85% of that of GHRP-6 (EC₅₀ 2.2 nM), and antagonist profiling showed it acts through the GHRP receptor rather than the GHRH receptor. In rats the ED₅₀ was 80 nmol/kg against 115 nmol/kg for GHRP-6, and in swine 2.3 nmol/kg against 3.9 nmol/kg, so on potency the two compounds are close. The separation came on specificity: none of the secretagogues tested affected FSH, LH, prolactin or TSH, but GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol, whereas Ipamorelin did not raise either above the level seen after GHRH itself, even at exposures more than 200-fold above its ED₅₀ for GH release. The authors described it as the first GHRP-receptor agonist with GHRH-like selectivity.

GH Release Profile

Ipamorelin produces a single, dose-dependent episode of GH release rather than a sustained elevation. A pharmacokinetic and pharmacodynamic study in healthy volunteers (Gobburu et al., 1999, Pharmaceutical Research 16:1412-1416) reported a terminal half-life of about 2 hours with dose-proportional kinetics, and a single GH episode that peaked within the first hour after exposure and then declined exponentially to negligible concentrations. The model used to describe it treated GH release as a zero-order burst of finite duration, which is the quantitative expression of “pulsatile.”

For a detailed review of Ipamorelin’s preclinical evidence, see our Ipamorelin research deep-dive.

CJC-1295: Extended-Duration GHRH Analog

CJC-1295 is a synthetic GHRH analog built on the first 29 residues of human GRF, the fragment that carries full receptor activity. It exists in two forms: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also called Modified GRF 1-29). Both carry four amino acid substitutions that slow enzymatic cleavage. The DAC version adds a lysine bearing an N-epsilon-3-maleimidopropionamide group at the C-terminus, which reacts in vivo with the free thiol of Cys34 on serum albumin to form a covalent conjugate (Jetté et al., 2005, Endocrinology 146:3052-3058). In that study the conjugate resisted dipeptidyl peptidase-IV in vitro, produced a 4-fold larger GH area under the curve over 2 hours than unmodified GRF(1-29) after subcutaneous administration to rats, appeared on the albumin band in Western blots of rat plasma within 15 minutes, and was still detectable in plasma beyond 72 hours.

A pharmacokinetic study of CJC-1295 DAC in healthy adults (Teichman et al., 2006, Journal of Clinical Endocrinology and Metabolism 91:799-805) put numbers on the duration: an estimated half-life of 5.8 to 8.1 days, a dose-dependent 2- to 10-fold rise in mean plasma GH lasting 6 days or more after a single exposure, and a 1.5- to 3-fold rise in IGF-1 lasting 9 to 11 days. For comparison, native GHRH(1-44) is cleaved by a plasma dipeptidyl aminopeptidase to the inactive GRH(3-44) fragment, with a half-life of 6.8 minutes in vivo (Frohman et al., 1986, Journal of Clinical Investigation 78:906-913).

CJC-1295 without DAC (Modified GRF 1-29) keeps the four stabilising substitutions but not the albumin linker, so its action is measured in minutes rather than days and it produces discrete GH pulses that track each administration. The preclinical case for the DAC form is Alba and colleagues (2006, American Journal of Physiology Endocrinology and Metabolism 291:E1290-E1294), who treated GHRH-knockout mice for 5 weeks: once-daily CJC-1295 normalised body weight and length, whereas the same amount every 48 or 72 hours improved growth without fully normalising it, and treated animals showed increased pituitary GH mRNA and somatotroph proliferation on immunohistochemistry.

For detailed comparison data, see our CJC-1295 DAC vs. No DAC research comparison.

Tesamorelin: GHRH Analog with Targeted Research Applications

Tesamorelin (C₂₂₁H₃₆₆N₇₂O₆₇S, MW 5135.9 g/mol) is human GHRH(1-44) amide with a trans-3-hexenoyl group attached to the N-terminal tyrosine. The non-clinical characterisation by Ferdinandi and colleagues (2007, Basic and Clinical Pharmacology and Toxicology 100:49-58) showed that this single modification made the peptide resistant to dipeptidyl aminopeptidase-IV, slowed its degradation in rat, dog and human plasma relative to native GRF(1-44), and produced marked increases in plasma GH and IGF-1 in pigs, rats and dogs with repeated administration; the apparent elimination half-life in dogs was 21 to 45 minutes. The compound is the only one of the four to have completed a full regulatory programme, which is why its pharmacology is unusually well documented for a GHRH analogue.

The pivotal 26-week phase 3 trial (Falutz et al., 2007, New England Journal of Medicine 357:2359-2370; 412 participants) reported that IGF-1 rose by 81.0% in the tesamorelin group and fell by 5.0% on placebo, which is the clearest published demonstration of sustained GHRH-receptor drive over months with a short-half-life analogue. The pharmacology matters more than the clinical endpoint for a research audience: a peptide cleared in under an hour still produced a sustained downstream IGF-1 signal when given daily, because IGF-1 integrates GH pulses over time.

Comparative Potency and Stability

Published head-to-head EC₅₀ comparisons between Tesamorelin, CJC-1295 and native GHRH in the same assay are not available, and any table that presents such numbers should be treated with suspicion. What the literature does support is a difference in strategy: Tesamorelin protects the DPP-IV cleavage site at the N-terminus and keeps the full 44-residue sequence, CJC-1295 truncates to the 29-residue active core, substitutes four residues and, in the DAC form, borrows albumin’s half-life. Both approaches address the same weakness of native GHRH, its 6.8-minute plasma half-life.

GHRP-6: First-Generation Ghrelin Mimetic

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, MW 873.01 g/mol) was the first synthetic GHS-R1a agonist to be characterised in detail. Bowers and colleagues (1984, Endocrinology 114:1537-1545) reported that the hexapeptide elicited dose-related GH release in vitro and in vivo without releasing LH, FSH, TSH or prolactin, that it was active in rats, monkeys, lambs and calves, and that after intravenous administration in rats GH rose within 2 minutes, peaked at 10 to 20 minutes and had usually returned to normal by 2 hours. Somatostatin inhibited the response, which located the action at the pituitary.

What separates GHRP-6 from Ipamorelin is the adrenal axis. In the swine experiments of Raun and colleagues (1998), GHRP-6 and GHRP-2 both increased plasma ACTH and cortisol at GH-releasing exposures, and Ipamorelin did not. The magnitude of the cortisol response varies with species, exposure and route, so a single percentage should not be quoted as a property of the compound; the reproducible finding is the direction of the effect and its absence with Ipamorelin.

GHRP-6 also engages appetite circuits. Locke and colleagues (1995, Life Sciences 56:1347-1352) injected GHRP-6 into the lateral ventricles of sated adult male rats and observed a nearly linear, statistically significant dose-response relationship between dose and the incidence of eating, while the plasma GH response was not dose-related, which showed the two effects are separable. This orexigenic effect is not unique to GHRP-6. Lall and colleagues (2001, Biochemical and Biophysical Research Communications 280:132-138) found that both Ipamorelin and GHRP-6 increased relative body fat in GH-intact mice, that Ipamorelin increased fat pad weight even in GH-deficient lit/lit mice, and that secretagogue treatment raised serum leptin and food intake. Ipamorelin’s selectivity is therefore a selectivity for the pituitary hormones, not an absence of ghrelin-receptor effects elsewhere.

Head-to-Head Comparison Table

Parameter	Ipamorelin	CJC-1295 (DAC)	CJC-1295 (no DAC)	Tesamorelin	GHRP-6
Receptor Target	GHS-R1a	GHRH-R	GHRH-R	GHRH-R	GHS-R1a
Half-life	~2 hours (Gobburu 1999)	5.8-8.1 days (Teichman 2006)	Minutes; no albumin binding	26-38 min per product monograph; 21-45 min in dogs (Ferdinandi 2007)	Short; GH back to baseline by ~2 h in rats (Bowers 1984)
GH Response	Single episode, efficacy 85% of GHRP-6 in vitro (Raun 1998)	2-10x mean GH for 6+ days (Teichman 2006)	Discrete pulse per administration	Pulsatile; IGF-1 +81% over 26 weeks (Falutz 2007)	Rise within 2 min, peak 10-20 min (Bowers 1984)
ACTH / Cortisol	No increase, even >200x ED50 (Raun 1998)	Not a GHRH-receptor effect	Not a GHRH-receptor effect	Not a GHRH-receptor effect	Increased (Raun 1998)
Appetite / Adiposity	Increased fat mass and food intake in mice (Lall 2001)	None reported	None reported	None reported	Dose-related eating after icv injection (Locke 1995)
GH Release Pattern	Pulsatile	Sustained elevation	Pulsatile	Pulsatile	Pulsatile

Key Research Findings

Ipamorelin matches GHRP-6 for GH-releasing potency in rat pituitary cells (EC₅₀ 1.3 versus 2.2 nM), rats and swine, but does not raise ACTH or cortisol at any exposure tested (Raun et al., 1998). Its human terminal half-life is about 2 hours and it produces a single GH episode (Gobburu et al., 1999). CJC-1295 DAC conjugates to albumin Cys34 within 15 minutes of injection in rats and remains detectable beyond 72 hours (Jetté et al., 2005); in humans its half-life is 5.8 to 8.1 days, with GH elevated 2- to 10-fold for 6 days or more and IGF-1 elevated 1.5- to 3-fold for 9 to 11 days after a single exposure (Teichman et al., 2006). Once-daily CJC-1295 normalised growth in GHRH-knockout mice, and less frequent administration did not (Alba et al., 2006). Native GHRH(1-44) has an in vivo half-life of 6.8 minutes because plasma DPP-IV removes its first two residues (Frohman et al., 1986); Tesamorelin’s N-terminal hexenoyl group blocks that cleavage (Ferdinandi et al., 2007). GHRP-6 releases GH within 2 minutes of intravenous administration in rats with a peak at 10 to 20 minutes (Bowers et al., 1984) and acts synergistically with GHRH by a mechanism independent of somatostatin inhibition (Bowers et al., 1991). Both GHRP-6 and Ipamorelin increase adiposity and food intake in mice by a GH-independent route (Lall et al., 2001).

Implications for Research Protocol Design

The choice of secretagogue depends entirely on the research question. Ipamorelin’s selectivity makes it the preferred tool compound when isolating GH-axis effects from cortisol and prolactin confounding, provided the study does not also need to exclude ghrelin-receptor effects on feeding. CJC-1295 DAC suits long-duration sustained GH elevation studies. CJC-1295 without DAC or Tesamorelin provide physiological pulsatile stimulation for shorter protocols. GHRP-6 remains relevant when studying the full ghrelin-axis activation cascade, including appetite and multi-hormonal responses.

Regardless of the compound selected, verified purity is non-negotiable for reproducible results. Maple Research Labs publishes independent third-party Certificates of Analysis reporting HPLC purity and mass spectrometric identity for tested lots, and our documentation standards set out what each report covers. Checking the analytical record against the compound in hand is what separates reliable experimental data from noise.

Each of the compounds compared above has a dedicated deep dive. Tesamorelin research covers the trans-3-hexenoic acid N-terminal cap that confers DPP-IV resistance and the adipose tissue and IGF-1 axis data from preclinical models, and the CJC-1295 pharmacology review details the four substitutions and the albumin bioconjugation chemistry that separate the DAC and non-DAC variants.

Browse our full catalog of research peptides including Ipamorelin, Tesamorelin, and CJC-1295 (no DAC), with published COA documentation. Orders placed by 2 PM PT (Mon–Fri) ship the same business day, from BC with tracking. For researchers transitioning from US suppliers following recent market changes, see our guide on Canadian alternatives to Peptide Sciences.

Single-compound receptor pharmacology for several of these agents is reviewed in our profiles of hexarelin and the CD36 pathway, GHRP-2 and ghrelin receptor agonism, and somatostatin and SSTR-mediated suppression of the GH axis.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

For peer-reviewed research on this topic, visit PubMed.